|View printer-friendly version|
|July 27, 2006 1:54 p.m.|
|Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-Remitting Multiple Sclerosis|
Jerusalem, Israel, July 27, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approved COPAXONE® (GA) 20 mg/day, whose efficacy and safety have been well established by three pivotal trials and over a decade of experience and clinical research. The study, called FORTE - FORTy mg Efficacy of glatiramer acetate is beginning the enrollment of approximately 1,000 patients in 160 centers across North America, Europe, Argentina and Israel.